Novel cancer immunotherapeutic agent targeting tumor and tumor immune microenvironment for the treatment of triple negative breast cancer
Technology Introduction:
This invention describes the discovery and development of BPR5K230, a potent, orally bioavailable AXL and MERTK selective kinase inhibitor targeting tumor and tumor immune microenvironment for the treatment of triple negative breast cancer patients who fail current therapies and whose tumors and immune cells overexpress AXL and MERTK. The current invention represents a novel target-driven, patient-stratified precision cancer medicine for tough-to-treat cancers.
National Health Research Institutes (NHRI) is a medical and health research organization in Taiwan, established as a public-funded foundation. Its main research areas include medicine, pharmaceuticals, public health, and other life sciences, as well as related technologies such as vaccine development.
Name：
Phone：037-206166 #35705
Address：35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan
A deep learning-powered novel artificial intelligence algorithm and syste m to assist in the identification of pneumoperitoneum on abdominal com puted tomography
Development of novel cannabinoid CB1receptor antagonists with high oral absorption and no central adverse effects for the treatment of cardiovascular diseases
Therapeutic Humanized Anti-CD24 Monoclonal Antibody for Precision Targeted Therapy of Triple-Negative Breast Cancer
Universal Hypoimmunogenic Allogeneic iPSC Source Bank: Driving Industrialization and Clinical Breakthroughs in Regenerative Medicine
Technology maturity：Others
Exhibiting purpose：Display of scientific results
Trading preferences：Negotiate by self
*Organization
*Name
*Phone
*Main Purpose
*Discuss Further
*Job Category
*Overall Rating
*Favorite Area
*Key Tech Focus
*Willing to Receive Updates?
Other Suggestions
Coming soon!